Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases

Introduction: Pulmonary sarcomatoid carcinomas (PSCs) are a rare subgroup of non-small cell lung cancer (NSCLC). In contrast to other NSCLCs, PSCs have a poor prognosis due to limited efficacy of radiation and chemotherapy. Therefore, other therapeutic approaches are needed. KRAS mutations occur in...

Full description

Bibliographic Details

Published in:	Case Reports in Oncology
Main Authors:	Jonas Frederik Schmidt, Dominik Entz, Frank Brasch, Martin Goerner
Format:	Article
Language:	English
Published:	Karger Publishers 2024-09-01
Subjects:	lung cancer pulmonary sarcomatoid carcinoma kras sotorasib
Online Access:	https://beta.karger.com/Article/FullText/540675